Valuation : Bioventix PLC

Market Cap 90.39M 123M 106M 99.02M 170M 11.71B 171M 1.17B 458M 5.91B 460M 450M 19.61B P/E 2026 *
12.9x
P/E 2027 * -
Enterprise Value 85.5M 116M 99.89M 93.66M 161M 11.08B 162M 1.11B 434M 5.59B 435M 426M 18.54B EV / Sales 2026 *
6.84x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
8.67%
Yield 2027 * -
1 week-1.14%
Current month+14.57%
1 month+14.57%
3 months+3.28%
6 months+13.44%
Current year-9.19%
1 week 1,660
Extreme 1660
1,800
1 month 1,450
Extreme 1450
1,800
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,550
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 23/12/2003
Director of Finance/CFO 67 01/07/2020
Director TitleAgeSince
Director/Board Member 67 25/11/2010
Chairman 66 01/11/2004
Director/Board Member 67 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
28/04/26 Buy

Chief Financial Officer

66 0.0013%
20/04/26 Free

Chief Executive Officer

9,967 0.1908%
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.14%-31.49%-54.47% 123M
-0.86%-1.43%+1.47%+18.51% 50.47B
-6.00%-0.75%+447.48%+524.26% 44.56B
-0.24%+0.74%+37.18%+16.57% 43.08B
-1.55%-2.07%+19.83%+73.63% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+121.63% 16.77B
-0.58%-2.12% - - 16.28B
-0.14%-1.37%+11.20%+27.13% 14.58B
-1.66%-1.25%+78.49%+39.02% 13.92B
Average -0.88%-1.36%+67.77%+90.50% 27.47B
Weighted average by Cap. -0.97%-1.21%+95.90%+126.36%

Financials

2026 *2027 *
Net sales 12.5M 16.95M 14.6M 13.69M 23.55M 1.62B 23.62M 162M 63.39M 818M 63.63M 62.25M 2.71B -
Net income 7.11M 9.64M 8.31M 7.79M 13.4M 922M 13.44M 92.43M 36.06M 465M 36.21M 35.42M 1.54B -
Net Debt -4.89M -6.64M -5.72M -5.36M -9.22M -634M -9.25M -63.61M -24.82M -320M -24.91M -24.37M -1.06B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
28/08/26 GBX 1,730.00 0.00% 5,360
27/08/26 GBX 1,730.00 -1.14% 4,205
26/08/26 GBX 1,750.00 0.00% 8,512
25/08/26 GBX 1,750.00 0.00% 4,489
24/08/26 GBX 1,750.00 0.00% 6,145
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock